Press Releases

No. 51 | 01. December 2016 | by Koh

DKTK Tübingen: €2.5 million for developing a novel cancer immunotherapy

Tumor cells coated with bispecific antibodies are attacked and killed by ac...
© J.Chiu, G.Jung

Scientists from the German Cancer Consortium (DKTK) at Tübingen University Hospital have developed a promising bispecific antibody for use in immunotherapy of prostate cancer and so-called squamous cell carcinoma, which can occur, for example, in the lungs, skin or uterus. The antibody binds to cancer cells as well as immune cells, thus provoking an immune response against the tumor. The Helmholtz Association now provides €2.5 million from its validation fund for the purpose of executing the next steps in the pharmaceutical development of the bispecific antibody.In the German Cancer Consortium (DKTK), the German Cancer Research Center (DKFZ) in Heidelberg joins up as a core center in long-term collaborations with university institutes and hospitals all over Germany that are specialized in research and treatment with a focus on oncology.

read more

No. 47 | 21. November 2016 | by ah

30 Years of the Cancer Information Service: More important than ever before!

What patients ask: Breast and prostate cancer are the most asked about.
© dkfz.de

Every year, more and more people are afflicted by cancer. In 2015 there were about 490,000 new cases in Germany alone. So, it is not surprising that the need for reliable information continues to grow: Last year, the German Cancer Information Service (KID) of the German Cancer Research Center (DKFZ) responded to 34,000 individual enquiries from all across Germany – more than ever before. Every month between 450,000 and 635,000 users accessed information on the website www.krebsinformationsdienst.de. Since 2014, doctors, caregivers, therapists and psychological counselors have utilized and valued the professional service krebsinformationsdienst.med.

read more

No. 46 | 14. November 2016 | by Koh

Research to combat pancreatic cancer

Illustration of the pancreas
© Wellcome Library, London

Cancer of the pancreas is one of the most aggressive types of cancer and therapies currently used are usually rather ineffective. Therefore, scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg are very committed in the fight against this disease. They discovered what makes this cancer type so resistant against drugs and why the tumors spread outside the pancreas so early. Based on these findings, they are testing schizophrenia medications, novel agents and even viruses in the treatment of pancreatic cancer.

read more

No. 45 | 04. November 2016 | by AM

DKTK Berlin: Boost for cancer therapies with tumors grown in petri-dish

Colon cancer cells growing into a 3-dimensional organoid cell culture in a ...
© Dr. Joseph Regan

Cancer can be caused by a variety of genetic mutations. One challenge medicine faces is finding tailor-made treatment for each patient based on their individual genetic differences. Scientists at the German Cancer Consortium (DKTK) at the Charité Comprehensive Cancer Center in Berlin have now received 2.6 million Euros so, together with regional biotechnology companies, they can make test systems available for personalized medication screening. The German Cancer Consortium (DKTK) builds a strong, long-term, institutional structure between the German Cancer Research Center (DKFZ) and universities and university hospitals all over Germany specially designated to clinical oriented cancer research.

read more

No. 44 | 24. October 2016 | by jg/Sel

Breast cancer month October: Information can help reduce fears

Evaluation of the user survey: for a large proportion of the 816 breast can...
© dkfz.de

Current studies show that patients with breast cancer benefit from reliable health information and education, reducing their fears and worries and improving their quality of life. The cancer information hotline (Krebsinformationsdienst, KID) at the German Cancer Research Center (DKFZ) in Heidelberg has been informing patients and their families for 30 years about all questions regarding cancer. In 50% of all enquiries on tumor localization, the subject of breast cancer is paramount.

read more

No. 43c | 17. October 2016 | by Koh

Gene fusion opens up treatment possibilities for aggressive brain cancer

© dkfz.de

Glioblastoma, an extremely aggressive type of brain cancer, is still mostly untreatable in children. Scientists from the German Cancer Research Center (DKFZ), Heidelberg University Hospital and an international consortium including the Max Planck Institute for Molecular Genetics (MPIMG) undertook a comprehensive analysis of glioblastoma genomes. In about ten percent of the cases, they found a previously unknown mutation that is treatable with a targeted drug that has already been approved. In experiments with mice, the investigators successfully used this agent to halt the growth of brain tumors with this mutation.

read more

No. 43 | 17. October 2016 | by ks/Sel

No billboard advertising of tobacco products - for the protection of minors

© dkfz.de

Germany is the only European country still allowing unrestricted advertising of tobacco products on large billboards. This type of advertising deliberately targets young consumers. A current publication by the German Cancer Research Center (DKFZ) shows that two thirds of adolescents and young adults are consciously aware of billboard advertising, and are thereby encouraged to start smoking. At the same time, a current survey suggests that the majority of the population supports a ban of billboard advertisement for tobacco products.

read more

No. 42a | 13. October 2016 | by nis

DKFZ-Junior scientist is awarded for vaccination against brain tumors

Theresa Bunse, Photo:private

For her work on the development of a vaccine against brain tumors, the Bayer Science & Education Foundation has awarded Dr. Theresa Bunse from the German Cancer Research Center (DKFZ) the 'Bayer Early Excellence in Science Award' 2016. The molecular biologist works in the Clinical Cooperation Unit of Neuroimmunology and Brain Tumor Immunology, investigating how the immune system can help in the defense against rare brain tumors by specifically blocking the growth of brain tumor cells.

read more

No. 42c | 14. October 2016 | by Sel

Making efficient use of Big Data in medicine

© dkfz.de

Large experiments and simulations in science today generate ever increasing amounts of data. In order to turn this data and information into insights and knowledge however, scientists also need storage capacities and analytical potential of a new quality. The Helmholtz Association is now leading the way in storing data permanently, securely and re-usably. In order to manage Big Data in science, the association has founded the Helmholtz Data Federation (HDF). Around 49.5 million Euros will be invested over the next 5 years in multi-thematic data centers and in modern data management. In the context of the HDF initiative coordinated by KIT in Karlsruhe, the DKFZ is responsible for the data accruing in healthcare.

read more

No. 42 | 12. October 2016 | by jg / Koh

Diet myths and cancer

Susanne Weg-Remers
© DKFZ/Tobias Schwerdt

Fasting starves tumors, foregoing sugar slows down cancer growth, alkaline foods protect from cancer: Many special diets and dietary patterns supposedly have the potential to prevent cancer or an existing disease from spreading in the body. Do these theories withstand scientific scrutiny? An interview with Dr. Susanne Weg-Remers, head of DKFZ's Cancer Information Service (KID), on World Food Day on October 16.

read more

RSS-Feed

Subscribe to our RSS-Feed.

to top